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Stem cellsIntroduction: The evaluation of cardiovascular side-effects is a critical element in the development of all
new drugs and chemicals. Cardiac safety issues are a major cause of attrition and withdrawal due to adverse
drug reactions (ADRs) in pharmaceutical drug development. Methods: The evolution of the HESI Technical
Committee on Cardiac Safety from 2000-2013 is presented as an example of an effective international
consortium of academic, government, and industry scientists working to improve cardiac safety. Results
and Discussion: The HESI Technical Committee Working Groups facilitated the development of a variety
of platforms for resource sharing and communication among experts that led to innovative strategies for
improved drug safety. The positive impacts arising from these Working Groups are described in this article.
© 2013 Elsevier Inc. Open access under CC BY-NC-ND license. 1. Introduction
The ILSI Health and Environmental Sciences Institute (HESI) was
established in 1989 to engage scientists from academia, government,
industry, and other research institutes to identify and move towards
resolution of global health and environmental issues of common and
critical concern (www.hesiglobal.org). HESI serves as a coordinating re-
source for these public–private partnerships by forming scientiﬁc com-
mittees. Through the HESI committee mechanism, scientists share, Center for Drug Evaluation
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NC-ND license. responsibility for identifying research topics, developing the research
program and study design, and interpreting and applying the study
results.
Cardiac safety issues have been and continue to be a major cause
of attrition and withdrawal due to Adverse Drug Reactions (ADRs)
in pharmaceutical drug development (Lasser et al., 2002; Laverty
et al., 2011; Piccini et al., 2009; Redfern et al., 2010; Stevens & Baker,
2009; Stummann et al., 2009). This attrition occurs in both the
nonclinical and clinical phases of development and can extend to
the post-market approval phase (Laverty et al., 2011; Redfern et al.,
2010). Furthermore, cardiovascular safety liabilities cause delays in
development, labeling restrictions, and negative impacts on physician
prescribing preferences, which reduce patient beneﬁt and limit the
potential for product success (Laverty et al., 2011; Redfern et al.,
2010). Effective cardiovascular evaluation is also critical in assessing
risk and subsequently protecting public health in the context
of exposure to environmental chemicals. A WHO report on the
global composite impact of chemicals on public health reported
that 16% (7–23%) of the total burden of cardiovascular disease was
attributed to environmental chemical exposure, corresponding to
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2011). In the context of both drug and environmental safety concerns,
the Cardiac Safety Technical Committee is working to develop improved
predictors of adverse cardiac events.
Drug cardiovascular safety has been a priority at HESI for over a
decade. In the year 2000, the need to better understand the scientiﬁc
basis for drug-induced delayed ventricular repolarization (QTc
prolongation) and Torsades de Pointes (TdP) was proposed as a timely
and important area of focus for HESI and the drug safety community. An
exploratory meeting was held in August of 2001 at ILSI headquarters in
Washington D.C. and later that year, HESI initiated an experimental
program to better characterize nonclinical models as predictors of
QTc prolongation. While this work matured and evolved from 2000
to 2008, a cardiac biomarker (i.e. troponin) research program was
initiatedwithin the context of a broadly basedHESI Biomarker develop-
ment committee. In 2008, the present-day Cardiac Safety Technical
Committee was endorsed by the HESI Board of Trustees to centralize
cardiac-focused efforts at HESI and synergize resources, expertise,
and outcomes. Since its inception, the Cardiac Safety Technical
Committee has expanded its program of work to support an improved
understanding of cardiovascular structure and function and its assess-
ment for safety and risk. This work can serve as an important resource
in reducing unanticipated adverse drug effects and evaluating the
potential impact of environmental or chemical exposures.
The diverse base of the Cardiac Safety Technical Committee allows
HESI to combine resources (intellectual, experimental, and ﬁnancial)
to pursue innovative strategies in a collaborative, non-biased approach.
This diversity comes from more than 21 industry organizations and 23
academic and government institutions from North America, Europe
and Asia. The members are a cross-disciplinary group of scientiﬁc
experts from the ﬁelds of clinical medicine, pathology, imaging, safety
pharmacology, physiology, toxicology, bioinformatics and many more.
The working groups of the Cardiac Safety Technical Committee
evolved from the expertise of the members, the need to address cardiac
safety issues as a major cause of attrition in drug development, and
concern around cardiac effects potentially resulting from environmental
exposures. The current working groups include: proarrhythmia, cardiac
biomarkers, integrated strategies, and stem cell-derived cardiomyocytes
subteam. The evolution and current projects of the working groups are
described in more detail below.
Since its inception in 2008, the HESI Cardiac Safety Technical
Committee has informed the practice and philosophy of cardiac safety
evaluation through a signiﬁcant body of novel research and expert
consultation. For example, the program has already:
• Increased the translational relevance of nonclinical studies by
developing data on the utility of cardiac troponin as a marker
of cardiac injury in nonclinical models (i.e. animal toxicity
testing),
• Supported accurate and efﬁcient safety decision-making by generating
and analyzing datasets that inform the selection and interpretation of
nonclinical models to predict TdP risk;
• Enriched the ﬁeld of cardiac safety by creating multi-disciplinary
forums for interaction and program formulation between structurally
focused cardiac safety scientists (e.g., pathology) and those primarily fo-
cused on cardiac functional endpoints (e.g., safety pharmacology); and
• Created a successful, multi-sector and international network of experts
that are coordinated through a committee infrastructure capable
of identifying and pursuing new challenges to address continued
cardiovascular safety issues.
In the last 4 years, this program of work has yielded 13 articles in
the peer-reviewed literature, presentations at 32 scientiﬁc meetings,
and 5 independently convened workshops or meetings. As the
Committee maintains several active work streams and is continually
adopting new areas of focus, additional impacts and outcomes are
anticipated in the months and years to follow (Fig. 1).2. Committee evolution
At the time of ﬁnalization of the ICH-S7A guideline (EMA, 2000), a
note was incorporated to the document stating that “there is no scientiﬁc
consensus on the preferred approach to, or internationally recognized
guidance on, addressing risks for repolarization-associated ventricular
tachyarrhythmia (e.g., TdP). A guideline (S7B) will be prepared to present
some currently available methods and discuss their advantages and
disadvantages. Submission of data to regulatory authorities to support the
use of these methods is encouraged.”
At the same time, HESI scientists identiﬁed cardiovascular safety
as a high priority topic and formed the Cardiovascular Safety Sub-
committee. This Subcommittee convened the ﬁrst working group in
2001 that explored drug-induced cardiac QT interval prolongation
and TdP. As a result, the Cardiovascular Safety Subcommittee formed
two subteams to further explore nonclinical in vitro and in vivo assays
as well as clinical studies to reﬁne formatting for ECGs, heart rate and
QT values.The Nonclinical Cardiovascular Studies Subteam engaged in com-
prehensive evaluation to compare the utility of selected
nonclinical approaches in assessing ventricular repolarization lia-
bility using a panel of 12 drugs with either no association or a
strong association to TdP as supported by extensive clinical data
on their propensity to elicit QTc prolongation and proarrhythmia
in man. These studies demonstrated a high degree of association
between hERG blockade potency and clinical QTc prolongation
and proarrhythmia. In vivo canine electrocardiograms (ECGs)
were also shown to be a good predictor of QTc prolongation and
arrhythmogenic risk. However, the canine Purkinje ﬁber assay
was found to show a low predictive value towards the clinical
outcomes. An additional goal of the studies was to provide infor-
mation on the interlaboratory variability in hERG assay results.
Results of these studies were inﬂuential in the subsequent devel-
opment of the Topic S7B guideline by the ICH Expert Working
Group, which requires the hERG assay and in vivo non-rodents
ECGs but does not require an action potential assay (e.g., the
Purkinje ﬁber assay) (J Koerner, personal communication, Feb-
ruary 22, 2013), (Hanson et al., 2006). The Methods and Meth-
odology Subteam developed background information on the
strengths and weaknesses of current cardiovascular toxicity assays
and determined the extent to which the existing assays worked
independently or in tandem to predict clinical outcomes. This
document also provided input to the ICH-S7B Cardiovascular Safety
Expert Working Group (http://www.emea.europa.eu/docs/en_GB/
document_library/Scientiﬁc_guideline/2009/09/WC500002841.pdf).
The Hanson et al. (2006) article was the ﬁrst of its kind to show
that nonclinical safety pharmacology data can be used to understand
cardiac safety. Detecting these cardiac risks earlier in the drug devel-
opment process and distinguishing a drug that prolongs QT interval
and is not proarrhythmic from one that leads to TdP has beneﬁts for
both the industry and patient safety. The results from that study
(Hanson et al., 2006), together with the Japanese Pharmaceutical
Manufacturer Association Project for Database Construction (JPMA
QT PRODACT) study (Nakaya & Hashimoto, 2005) were instrumental
in deﬁning the nonclinical cardiac repolarization assays required
before ﬁrst administration of a drug to humans as outlined in the
ICHS7B (EMA, 2005).
The Cardiovascular Pro-Arrhythmia Models Project Committee
replaced the previous committee in 2005 to further focus on
drug-induced TdP. This project committee convened a workshop
that resulted in several publications on improving predictivity based
on the workshop recommendations (Bass, Darpo, Breidenbach,
et al., 2008; Bass, Darpo, Valentin, Sager, & Thomas, 2008). The main
Fig. 1. Key HESI Cardiac Safety Technical Committee milestones.
1 The HESI Cardiac Safety Technical Committee mission is: to reduce unanticipated
adverse cardiovascular events by developing and disseminating improved data/data
analysis, approaches, testing methods/guidelines/best practices, and resources for the
evaluation of cardiac toxicity in in-vitro, animal, and clinical settings, and to unify an
interdisciplinary team of scientists (toxicology, physiology, pathology, pharmacology,
chemistry, clinical medicine, modeling, etc.) to address issues of contemporary concern
relative to human cardiac safety.
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the hERG assay, which evaluates the rapid component of the delayed
rectiﬁer potassium current (IKr); conduct a series of studies to collect
beat-to-beat QT and RR interval data in key species and models, further
standardize the process of model and protocol development, select test
parameters for veriﬁcation studies and; develop a multi-institution val-
idation program. Several programs of work emerged as a consequence
of this workshop, although not necessarily managed under the HESI
umbrella, e.g., i) the need to look at cardiac contractility, and evaluate
assay sensitivity in the nonclinical arena (Sarazan et al., 2011); see
below)); ii) the evaluation of the predictive value of non-clinical
repolarisation assays to QTc in Phase I clinical trials (Valentin et al.,
2009); and iii) the development of nonclinical cardiovascular best
practices (Leishman et al., 2012).
3. Current working groups
The Cardiac Safety Technical Committee formed in 2008 and
absorbed the activities of the Cardiovascular Pro-Arrhythmia Project
Models Committee as well as cardiac-related activities from the
Development and Application of Biomarkers of Toxicity Technical
Committee. This reorganization allowed HESI to create opportunities
for synergy, share resources and expertise between the working
groups and avoid duplication of efforts across HESI.
The Committee began by facilitating a variety of research collab-
orations that brought together nonclinical scientists and clinicians
to address issues of contemporary concern relative to clinicalcardiac safety. The Committee's research activities collectively and
independently responded to the FDA's Critical Path Opportunities List
which called for innovative and collaborative approaches to identifying
markers and mechanisms of cardiac toxicity (Piccini et al., 2009).
The committee developed a mission1 and three working groups
were collated to meet the mission: Cardiac Pro-Arrhythmia Models,
Biomarkers of Cardiac Toxicity and an Integrative Strategies Working
Group. While these groups have evolved over time, they continue to
develop and disseminate improved data, approaches, and resources
for the evaluation of nonclinical and clinical cardiac safety.
4. Pro-arrhythmia Working Group
The objectives of the Cardiovascular Pro-arrhythmia Working
Group, are three-fold i) to assess the concordance between nonclinical
repolarization assays and clinical measures of QT interval prolongation;
ii) to investigate the mechanisms for any discrepancy identiﬁed
between nonclinical and clinical results and to determine viable
and successful alternative approaches to identify these compounds;
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(Trepakova, Koerner, Pettit, & Valentin, 2009). To that end in 2009,
the working group began a retrospective analysis of nonclinical and
clinical data submitted in support of Investigational and New Drug
Applications (INDs and NDAs) as well as a supplemental literature
review of public domain data to establish a quantitative integrated
risk assessment for each compound and assess concordance. These
activities represent the ﬁrst phase of a long-term project to assess con-
cordance between nonclinical and clinical QT prolongation. Ultimately,
the outcome of such a project might alleviate the need for a mandatory
requirement for a thorough clinical assessment of QT/QTc for all drugs.
As was noted by Dr. N. Stockbridge, Director of the Division of
Cardiovascular and Renal Products, US FDA CDER, in 2008, “The HESI
Cardiovascular Pro-Arrhythmia Models Project is an important compo-
nent of our community approach to advance the science behind
the regulatory response to the proarrhythmic potential of drugs. This
particular effort may result in a shift from heavy reliance upon clinical
evaluation of QT to a battery of nonclinical tests. And, even if the time
is not upon us for such a transition, the meta-analysis of existing
data is a landmark in the process of validating the nonclinical testing
strategy” (ILSI-HESI, 2008).
The database effort was completed in the third quarter of 2012
and is the culmination of over three years of collaborative efforts
among industry members and FDA. This ground-breaking program
is the only example at this time of a joint public–private effort to
analyze IND&NDAdata submitted to a regulatory body.2 The successful
execution of this program required a signiﬁcant effort and commitment
by all parties and demonstrates their shared goal of utilizing existing
data sets as a resource for improving safety decisions and optimizing
resources. A total of 257 compounds were reviewed and 150 included
in theHESI/FDAdatabase; another set of 185 compoundswere included
in the literature review. Publication of the results of these analyses is
pending, but the process has already generated valuable discussion
and insights that are likely to improve the way in which these data
are generated, submitted, and analyzed.
Not only has the HESI/FDA database impacted our understanding of
nonclinical to clinical concordance, the partnership on this project has
spurred internal FDA discussions on signiﬁcance of ﬁnding acceptable
ways to securely share submitted data in a way that allows analysis
of the pooled data to beneﬁt the broader scientiﬁc community. This
collaborative effort was recently commended in Science Translational
Medicine as an exemplary model for leveraging nonclinical and clinical
data (Dambach & Uppal, 2012).
Once the Pro-Arrhythmia Working Group members submit the
HESI/FDA database and literature review manuscripts, they plan to
initiate phase 2 of the project, which is to investigate the mechanisms
of non-concordance. This effort may include evaluation of integrated
sensitivity values for QTc effects, pooling available in-house data
to assess positive controls, or use existing and new data to develop
a position paper about the importance of high quality nonclinical
arrhythmia and TQT study conduct and reporting practices.5. Cardiac Safety Biomarkers Working Group
Initiated as the Expert Working Group (EWG) on Biomarkers
of Drug-Induced Cardiac Toxicity, the group reviewed biomarkers of
cardiac injury, which are deﬁned in this paper as measurable biological
molecules found in blood, other body ﬂuids, or tissues that are signs of a
cardiac condition, biologic process or disease, and advocated the use of
cardiac troponin – amarker in use at the time by cardiologists and some
other physicians –as a nonclinical biomarker to predict and monitor2 Note: Dataset was housed at the FDA and data were anonymized prior to being
shared with the Committee for analysis and discussion.cardiac injury in drug toxicity studies (Wallace et al., 2004). In 2008,
the EWG was expanded by the addition of scientists from related
disciplines and moved from HESI's Development and Application of
Biomarkers of Toxicity Technical Committee to the newly formed HESI
Cardiac Safety Technical Committee as the Cardiac Troponin Working
Group. The working group focused on the analytical validation of
available human cardiac troponin assay kits in a variety of laboratory
animals including rats, dogs, and monkeys. Collaborating with
Fred Apple, clinical chemist at the University of Minnesota, the group
evaluated 10 commercially available assays developed for measurement
of cTn in human serum or plasma samples to compare measures of the
assay's performance in laboratory animals. This program provided
critical foundational data to support the technical feasibility of ‘reverse
translation’ of cardiac troponin in nonclinical models. Speciﬁcally, the
research identiﬁed important differences in assay reactivity and
precision among species and identiﬁed those assays most suited to
particular species as well as recommending against the use of some
of the commercial assays for accurate measurement of cTn concentra-
tion in speciﬁc nonclinical (laboratory animal) phase testing (Apple,
Murakami, Ler, Walker, & York, 2008).
Having successfully deﬁned the analytical properties of cTn assays in
laboratory animals, the group began the biologic validation of cTn as a
marker of cardiac injury in nonclinical studies. Using the isoproterenol-
treated rat as an animal model of acute cardiac myoﬁber injury, the
group compared and contrasted the ability of several biomarkers to
predict and monitor myocardial injury, plotted the kinetics of cardiac
troponin release, and correlated results of cTn concentration with
detailed histopathologic examination of cardiac tissue (Clements et al.,
2010). This study provided novel insights into the kinetics of cTn release
and thus its potential value as a prodromalmarker in nonclinical studies.
The data demonstrated that increases in cTn concentration precede his-
tologic evidence of cardiac injury, and that cTn is therefore well-suited
for further study as a nonclinical, predictive biomarker of drug-induced
acute cardiomyocyte injury. The signiﬁcance and quality of this
publication were recognized by the Society of Toxicologic Pathology
who awarded it their “Best Paper” commendation for the year 2010.
Next, the Cardiac Troponin Working Group bridged existing efforts
within HESI to analyze cardiac troponin concentrations in a model of
chronic, low level cardiac injury in rats. The working group provided
data for a joint HESI Biomarkers-HESI Committee on Genomics
doxorubicin study that compared assays for cTnI and cTnT with an
ultra-sensitive cTnI assay (Reagan et al., 2013). The group also provided
a detailed histopathologic analysis of the vacuolar changes within the
myocytes of the cardiac atria and ventricles of rats given doxorubicin.
The assays for cTnI and cTnT concentrations and the high-sensitivity
cTnI assay effectively identiﬁed cardiac injury in doxorubicin-treated
rats. Further these studies showed that the pattern of release of cTn
after cardiac injury is affected by the histologic nature of the lesion
within the heart. Vacuolar changes within cardiac myocytes, such as
those induced by doxorubicin administration in rats, result in smaller,
more subtle increases in cTn release compared to the acute necrosis
typical of isoproterenol and other better-characterized cardiac toxicants.
The studies described above provided previously unavailable data
demonstrating the potential to link nonclinical toxicity study outcomes
to a measurable clinical endpoint via cardiac troponin (Berridge et al.,
2009). These data and the efforts of theHESI Development and Applica-
tion of Biomarkers of Toxicity Technical Committee were cited in
materials submitted to FDA as part of a 2012 FDA decision to
qualify the conditional use of cTnI and cTnT as biomarkers in safety
assessment studies. Nonclinical characterizations of troponin bio-
marker pathobiology have also effectively informed clinical applica-
tions of troponin outside of traditional applications like acute
coronary syndrome patients (Berridge et al., 2009).
In 2010, the working group broadened its mission to include
evaluation of novel markers of cardiac physiology and safety while
continuing its evaluation of cardiac troponin (and changed its name
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Group.) The working group is evaluating several potential predictive
biomarkers of cardiovascular toxicity. A systematic approach is being
used to select analytes that can be integrated into nonclinical testing
and subsequently incorporated into early clinical trials to bridge
multiple stages of drug development. In preparation for this work, a
recent survey paper from the Cardiac Biomarkers Working Group
identiﬁed important gaps in current nonclinical drug development
practices of the biopharmaceutical industry (Schultze et al., 2012).
Thromboembolism is a common cause of morbidity and mortality
for patients with pre-existing cardiovascular disease. Non-invasive,
antemortem nonclinical testing lacks adequate sensitivity to identify
prothrombotic conditions in animals. The survey results demonstrated
a critical need for validated, predictive biomarkers of hypercoagulability
and subclinical thrombosis for use in laboratory animal safety studies.
The working group is therefore reviewing animal models of altered
hemostasis that mimic human prothrombotic conditions and investi-
gating novel analytes relevant to the pathologic pathways leading to
overt cardiovascular complications of drug therapy. Future translational
studies are planned for 2013 and beyond to qualify and validate
new biomarkers that improve the efﬁciency and reliability of drug
safety assessment practices.
6. Integrated Strategies Working Group
The Integrated Strategies Working Group formed as a result of a
June 2009 HESI Think Tank entitled, “Current Practice In Structural
and Functional Toxicity: Issues And Opportunities.” That meeting
focused on the potential to more effectively synergize approaches to
cardiovascular structure and function and to create new networks for
engaging both clinicians and nonclinical scientists in the design,
conduct, and interpretation of drug safety studies. During the meeting,
participants identiﬁed the need for a more integrated approach to
conducting nonclinical assays to create more readily translatable and
informative data of value to the clinic (Pettit, Berridge, & Sarazan,
2010). In late 2009, two working groups (Functional CV strategies,
and Integrative CV strategies) were established to address some of the
challenges identiﬁed at this workshop. The Functional Cardiovascular
Strategies Working Group published the outcome of their deliberations
in the International Journal of Toxicology in 2011 (Sarazan et al., 2011).
The HESI Functional Cardiovascular Working Group concluded that
the public health threat due to drug related QT interval prolongation
and associated proarrhythmia has been largely resolved. The group
acknowledged that further work is indicated to improve the selectivity
of nonclinical assays to avoid eliminating promising drugs that may not
be proarrhythmic in clinical use. The working group also found that
drug effects on blood pressure and cardiac function (contractility) are
very important, although controversy exists regarding optimal animal
models, parameters and their interpretation. For many compounds,
cardiovascular safety pharmacology data are now being collected in
repeat dose toxicology studies in addition to, or in the case of biologics
instead of, purpose-designed safety pharmacology telemetry studies.
The sensitivity of nonclinical cardiovascular function studies has
historically been poorly characterized (if at all). Therefore, these studies
have had little impact on regulatory and clinical decision making.
In 2012, the Integrative Strategies Working Group decided to focus
on the importance of drug effects on cardiac function (contractility)
and the characterization of the sensitivity of nonclinical cardiovascular
function studies. The working group further pursued these through
a collaboration to conduct prospective conscious dog studies using
implantable telemetry and using positive control drugs with known
clinical effects. When these global multi-site studies are completed
and the data analyzed by the HESI working group during 2013,
objective information on the actual sensitivity and speciﬁcity of in vivo
contractility assays will be shared internationally in posters, lectures
and peer-reviewed manuscripts. The team is also evaluating proposalsfor use of diseased animal models to assess structural and functional
effects in a nonclinical setting that more closely resembles potential
patient health status.
The predictive cardiovascular strategies subgroup took a broad
look across contemporary nonclinical cardiovascular risk assessment
paradigms and put them in the context of persisting clinical
challenges to identify opportunities for bridging that gap (Berridge
et al., 2013). A particular interest was put on nonclinical strategies
that might better inform clinical outcomes (i.e. that would be more
predictive). A number of primary gaps were recognized: i) Short
duration nonclinical safety studies do not model chronic outcomes
in either clinical or nonclinical studies; ii) Robust assessment of CV
function is not a routine component of repeat-dose general toxicity
studies; and iii) Nonclinical safety studies do not model diseased
patient populations.
Likewise, opportunities for enhancing current practices were also
recognized and represented possible ‘actionables’ for our consortium
working group. A few of the opportunities identiﬁed are being interro-
gated by existing groups — e.g. circulating biomarkers and hemostasis
assessments (HESI Cardiac Biomarkers WG, PSTC Cardiac Hypertrophy
WG), microRNAs (HESI Application of Genomics to Mechanism-Based
Risk Assessment Technical Committee), preclinical imaging (HESI
Preclinical Imaging WG), and functional endpoints in repeat-dose
toxicity studies (Safety Pharmacology Society). An opportunity not
being explored by any otherworking group to our knowledge but a sub-
ject of increasing conversation in multiple venues is that of alternative
animal modeling for cardiovascular risk identiﬁcation. Accordingly,
this group is exploring this further and will establish clinical partner-
ships to better understand patient susceptibilities that might be the
focus of alternative modeling approaches. This group is very aware of
the sensitivities and complexity of ‘diseased’models for risk assessment
and is therefore also exploring ‘stressed heart’models (e.g., dobutamine
stress) as potentially informative tools.7. Stem cell workshop
In 2011, the Integrated Strategies Working Group adopted a
proposal to convene a workshop focused on stem-cell derived
cardiac myocytes (SC-CM) and their potential role in cardiac safety
assessments. Stem cell technology is an emerging area of science
that has the potential for broad biomedical applications in
nonclinical and clinical research, including the evaluation of drug
or chemical induced cardiac toxicity (Kraushaar et al., 2012;
Sison-Young et al., 2012). However, the harmonized utilization and
application of human SC-CM in the cardiac safety evaluation of drug
candidates and chemicals will require a coordinated effort to validate
and qualify the use of SC-CM for risk assessment (Micheel & Ball,
2010). To meet this need a HESI workshop, co-sponsored by the
Safety Pharmacology Society (www.safetypharmacology.org), brought
together experts to address this issue (“Pluripotent Stem Cells:
Applications for Cardiovascular Risk Assessment”; March 18–19, 2013;
Amgen Inc., Cambridge, Massachusetts.) The objective of this workshop
was to assemble an international and multi-disciplinary group of
scientists to discuss the use of induced pluripotential SC-CM, and the
associated analytical technologies used to assess changes in SC-CM
function, for the nonclinical cardiovascular risk assessment of pharma-
ceuticals and chemicals. The workshop focused on key topics, such as:
i) What are current approaches to applying and developing stem
cell-derived cardiomyocyte assay platforms? ii) How can this stem
cell technology be used to inform CV risk assessment or pathway
evaluation now, and what are the opportunities in the future? and
iii) What additional standards or data are needed to facilitate the use
of these data for translational science decision-making? A publication
of the key discussion points and recommendations from the workshop
is planned.
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Since the program's initiation in 2000, the HESI Cardiac Safety
Technical Committee has matured and developed into several working
groups that function in tandem to create a robust, multi-disciplinary
portfolio. By identifying predictive and translational biomarkers
of cardiovascular toxicity, developing best practice guidelines,
optimizing testing strategies, and promoting innovative technologies
and approaches, the HESI Cardiac Safety Technical Committee has had
and will continue to have signiﬁcant impact on the efﬁciency and
translational relevance of cardiac safety evaluation. This work supports
public health via safe medicines and environments. The committee's
efforts have been shared widely through numerous scientiﬁc publica-
tions, presentations, meetings and workshops. In addition, new venues
for collaboration, data compilation and analysis, and dissemination of
results and guidelines are now in development. Numerousmanuscripts
reﬂecting the work of the committee are in development and commu-
nication and outreach efforts to further share the work are planned.
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